BARCELONA, Spain — For the first five months of 2007, the future of the Codelink bioarray platform looked bleak. GE Healthcare had pledged to help customers adopt other platforms, and shutter the business and sell off its assets should a buyer not be found. Then, a last-minute deal with Applied Microarrays in April secured the future of the platform.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.